Pharmaceuticals company Marksans Pharma announced Q4FY25 & FY25 results Q4FY25 Financial Highlights: Operating revenue stood at Rs 708.5 crore., up by 26.5% YoY driven growth across key markets, led by US region Gross profit stood at Rs 383.2 crore., up by 32.1% YoY, with a gross margin expansion of 228 bps YoY to 54.1%. Growth is attributed to softening of raw material prices and a better product mix. EBITDA stood at Rs 125.8 crore. up by 14.7% YoY, with a margin of 17.8% EPS is at Rs 2.0, an incroreease of 15.7% FY25 Financial Highlights: Operating revenue stood at Rs 2,622.8 crore., up by 20.5% YoY driven by growth across all markets US business grew by 34.7% YoY UK & Europe grew by 9.2% YoY Australia & New Zealand grew by 15.5% YoY Gross profit came in at Rs 1,479.1 crore., up by 29.8% YoY, with a gross margin of 56.4% EBITDA stood at Rs 528.6 crore., up by 15.3%, with an EBITDA margin of 20.2% EPS grew by 21.3% YoY to Rs 8.4 Mark Saldanha, Managing Director of the Company said “We are pleased to announce another year of robust performance; we have achieved highest ever annual revenues and profits. In FY25, we witnessed strong performance across all our markets, the US market has been a key growth driver with 35% YoY increase in revenue. Our OTC segment’s performance is at all-time high, crossing Rs 2000 crore in revenue, a testament to our focus and execution on expanding the OTC product pipeline. Looking forward, we continue to strengthen our foundation by increasing the capacity and strengthening our product pipeline. We are optimistic about building on this momentum and create more value for our stakeholders in the coming years” Result PDF